Skip to main content
x

Recent articles

The FDA's "radical transparency", up to a point

A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steps up for Glenmark's multispecific

The deal for ISB 2001 is worth $700m up front.

More problems for BioNTech & Roche’s neoantigen shot

Autogene cevumeran goes on hold in adjuvant bladder cancer.

Early validation for in vivo Car-T

ESO-T01 delivers its first four multiple myeloma case reports.

When two antigens are better than one

Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.

Arvinas leader departs under a Pfizer-shaped cloud

Weeks after criticising the group’s big pharma partner, John Houston is on his way out.